Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArdelyxARDX -1.10%62 Net Cash per Share is $-0.58 as of Jun. 2026. GuruFocus rates ARDX with a GF Score™ of 62/100 and a GF Value™ of $8.76 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 763 Biotechnology companies, Ardelyx ranks worse than 131061.47% on this metric.
The historical rank and industry rank for Ardelyx's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of Ardelyx was 146.00. The lowest was 1.11. And the median was 3.90.
ARDX's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 5.07 * Ranked among companies with meaningful Price-to-Net-Cash only.
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Ardelyx Net Cash per Share Related Terms
Ardelyx Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Ardelyx's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARDX vs IMMX, WVE, CADL: Net Cash per Share Comparison
For the Biotechnology subindustry, Ardelyx's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Ardelyx's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Ardelyx's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx (ARDX) has a Net Cash per Share of $-0.58 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Ardelyx and its competitors. According to the industry distribution chart, Ardelyx ranks #999999 out of 763 companies in the Biotechnology industry.
Is Ardelyx's Net Cash per Share too high?
Ardelyx's current Net Cash per Share is $-0.58. Based on the distribution chart, Ardelyx ranks #999999 out of 763 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ardelyx has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's Net Cash per Share compare to IMMX and WVE?
According to the Biotechnology industry distribution chart, Ardelyx ranks #999999 out of 763 companies for Net Cash per Share. This places Ardelyx in the lower half of its industry. The industry median Net Cash per Share is 5.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.07, based on 763 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Ardelyx and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ardelyx's current Net Cash per Share is $-0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is $8.76, compared to a current price of $3.58 — trading 59.1% below its estimated fair value. The current Net Cash per Share is $-0.58. Ardelyx's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Ardelyx (ARDX), the current Net Cash per Share is $-0.58 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ardelyx (ARDX) Overvalued in 2026?
Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued.
The current stock price of $3.58 is trading 59.1% below its estimated GF Value™ of $8.76.
GuruFocus considers Ardelyx to be Possible Value Trap.
Key valuation signals for ARDX:
Net Cash per Share: $-0.58
GF Value™: $8.76 vs. price of $3.58 (59.1% below fair value)
No single metric tells the full story. See the ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
62GF Score
Get the complete analysis for ARDX
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARDX has been successfully added to your 
